We are now able to safely target BCL-XL using proteolysis targeting chimeras (PROTACs, such as DT2216) without causing appreciable platelet toxicity (thrombocytopenia) as recently reported by our group [16–20]. The gene discussed is BCL2L1; the disease is Thrombocytopenia.